Bogle Investment Management’s Travere Therapeutics TVTX Stock Holding History

Bogle Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-23,978	Closed	-$489K	–	322
2020 Q2	$489K	Buy	+23,978	New	+$382K	0.08%	209
2020 Q1	–	Sell	-98,796	Closed	-$1.4M	–	351
2019 Q4	$1.4M	Buy	+98,796	New	+$1.26M	0.13%	155
2018 Q4	–	Sell	-105,859	Closed	-$3.04M	–	422
2018 Q3	$3.04M	Sell	105,859 -10,957	-9%	-$313K	0.22%	126
2018 Q2	$3.18M	Buy	116,816 +29,436	+34%	+$784K	0.23%	124
2018 Q1	$1.95M	Buy	87,380 +33,293	+62%	+$793K	0.15%	151
2017 Q4	$1.14M	Buy	54,087 +4,112	+8%	+$94K	0.08%	215
2017 Q3	$1.24M	Buy	+49,975	New	+$1.1M	0.08%	204
2017 Q1	–	Sell	-200,196	Closed	-$3.79M	–	381
2016 Q4	$3.79M	Buy	200,196 +164,349	+458%	+$3.36M	0.26%	122
2016 Q3	$802K	Buy	35,847 +15,304	+74%	+$291K	0.06%	269
2016 Q2	$365K	Buy	+20,543	New	+$333K	0.03%	338
2014 Q2	–	Sell	-130,917	Closed	-$2.77M	–	378
2014 Q1	$2.77M	Buy	+130,917	New	+$2.01M	0.19%	162

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bogle Investment Management's TVTX Position: Q3 2020 in Review

Bogle Investment Management sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 23,978 shares — an estimated $489K sold.

Bogle Investment Management first reported a position in TVTX in Q1 2014 and held it in 11 quarters. The position peaked at $3.79M in Q4 2016. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

Bogle Investment Management reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
Bogle Investment Management sold 23,978 Travere Therapeutics shares in Q3 2020, an estimated $489K.
Bogle Investment Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 11 quarters.
Bogle Investment Management's Travere Therapeutics position peaked at $3.79M in Q4 2016.
134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.